Rheumatology

Baricitinib treatment is associated with greater improvements in patient-reported outcomes than methotrexate monotherapy, suggests an analysis of the RA-BEGIN trial.

Changing sedentary behavior needs to be a focus for patients who undergo total knee or hip joint replacement, US researchers maintain.

Targeting factors such as inflammation and disease activity in patients with rheumatoid arthritis could help reduce their risk for cardiovascular disease, study findings suggest.

A Canadian research team has pinpointed several sociodemographic, disease, and treatment parameters associated with adherence to medication in patients with rheumatoid arthritis.

Results of a US study suggest that herpes zoster infection is associated with an increased risk for giant cell arteritis, but antiviral treatment and vaccination are unlikely to reduce this risk.

Evidence from a systematic review suggests that weight loss is likely to be beneficial for overweight and obese patients with gout.

An international taskforce has developed consensus-based recommendations for the evaluation and use of biosimilars to treat rheumatic diseases.

Two studies published in Arthritis & Rheumatology explore strategies for reducing herpes zoster risk among patients with rheumatoid arthritis treated with the Janus kinase inhibitor tofacitinib.

The ratio of absolute neutrophil to lymphocyte count could be an effective additional biomarker for detecting infection in patients with systemic lupus erythematosus, research suggests.

The interleukin-6 inhibitor sirukumab could offer a therapeutic option for patients with active rheumatoid arthritis despite treatment with disease-modifying antirheumatic drugs, results of the phase III SIRROUND-D study suggest.

A Nordic cohort study has identified factors associated with the development of uveitis among children with juvenile idiopathic arthritis.

Treatment with interleukin-6 receptor blockers could be an effective option for patients with cancer who develop severe arthritis in response to immune checkpoint inhibition therapy, say researchers who describe three such cases in the Annals of the Rheumatic Diseases.

Dyslipidemia, abdominal obesity, and alcohol consumption are associated with a poor response to urate-lowering therapy among patients with gout, researchers report.

Patients with osteoarthritis or rheumatoid arthritis who take ibuprofen are more likely to experience an increase in systolic blood pressure than those taking celecoxib, results of the PRECISION-ABPM study suggest.

Open-label extension results from a phase IIb trial suggest that baricitinib continues to be well tolerated and efficacious for up to 2.5 years among patients with rheumatoid arthritis.

Intravenous golimumab is a promising treatment option for patients with psoriatic arthritis, results of the placebo-controlled GO-VIBRANT trial suggest.

Click through to read more on this decision

A score calculated from laboratory results could help to identify whether patients with rheumatoid arthritis are more likely to respond to treatment with a tumor necrosis factor inhibitor or to the interleukin-6 inhibitor tocilizumab, researchers report.

Two follow-up analyses of a randomized trial suggest that the etanercept biosimilar SB4 and its reference product have similar long-term efficacy and safety profiles in patients with rheumatoid arthritis, and switching to the biosimilar is not associated with adverse events or loss of response.

Women with gout are more likely to require total knee replacement for severe knee osteoarthritis than those without gout, study results suggest.